Bohai adds additional pharmaceutical products to Traditional Chinese Medicine portfolio

Bohai Pharmaceuticals Group, Inc. (OTCBB/OTCQB: BOPH), a China-based pharmaceutical company engaged in the production, manufacturing and distribution of Traditional Chinese Medicine (TCM) in China, today announced the introduction of five additional pharmaceutical products to its portfolio of TCM offerings.

“We are pleased to report this significant expansion of our product offering”

The new products, drawn from the stable of 29 products that Bohai is already licensed to manufacture, significantly expand Bohai's pharmaceutical offering from 10 to 15 products. Three of the new products were introduced to the Chinese market in April 2010, with the remaining two products introduced in May 2010. In addition to the 15 TCM products now in production, Bohai holds the rights to produce 14 other TCM formulations in China.

"We are pleased to report this significant expansion of our product offering," said Mr. Hongwei Qu, President and Chief Executive Officer of Bohai Pharmaceuticals. "Each of Bohai's recently introduced products is specifically tailored to address a particular area of the body, ranging from stomach aches to chronic joint and back pain. In order to launch the products, a sales campaign was introduced to increase the general public's awareness of these new offerings. As our sales initiatives take hold, we look forward to reporting on the progress of our expanded portfolio in fiscal 2011."

Out of the five recently introduced products, three are prescription drugs and the remaining two are non-prescription, or Over-the-Counter (OTC) medicines. The new products are intended to supplement, but not diminish, Bohai's sales strategies for it flagship offerings, Tongbi Capsules and Tablets and Lung Nourishing Cream. The company also indicated that initial sales of these products will not contribute materially to its June 30, 2010 year end results.

Mr. Qu continued, "In addition to this announcement, we look forward to bringing our US investors more detailed profile descriptions of these recently introduced products over the next several weeks, including in our forthcoming 10-K annual report. We believe our capital raise in January, combined with our expanded TCM portfolio and proactive sales initiatives will serve to drive our revenue and earnings potential in the new fiscal year."

Bohai Pharmaceuticals Group recently became a US publicly listed company in early 2010, along with a concurrent $12 million private raise, and expects to achieve record levels of revenue and earnings for its fiscal year ending June 30, 2010 due to its corporate growth initiatives and expertise in China's expanding pharmaceutical and Traditional Chinese Medicine (TCM) industries. The company is committed to establishing itself as a leading manufacturer and distributor of TCM throughout China's major cities and rural areas. The company believes it is positioned to capitalize on the rapidly-growing demand for TCM products in China, which is anticipated to increase due to China's rising middle class, increasing elderly population and Chinese government support.